Clinical Study of ATTR-CM

Zhejiang University

Status and phase: Enrolling; Phase 4

Conditions: Transthyroxine Amyloidosis Cardiomyopathy

Treatments: Drug: ATTR-CM

Study type: Interventional

Funder types: Other

Identifiers

NCT04935021

2021-0132

Details and patient eligibility

About

In this study, patients with ATTR-CM or gene carriers were selected to study the diagnosis and treatment, and long-term follow-up was conducted.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
• Patients who have the ability to understand the test and can cooperate with investigators

Exclusion criteria

• Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

ATTR-CM

Experimental group

Description:

Patients or Gene carrier

Treatment:

Drug: ATTR-CM